Lyra Therapeutics (LYRA) Restructuring Costs (2024 - 2025)

Quarterly Restructuring Costs fell 85.54% to $238000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, down 86.1% year-over-year, with the annual reading at $1.5 million for FY2025, 86.24% down from the prior year.

Lyra Therapeutics' Restructuring Costs history spans 2 years, with the latest figure at $238000.0 for Q4 2025.

  • Restructuring Costs came in at $238000.0 for Q4 2025, up from -$21000.0 in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $6.4 million in Q2 2024 to a low of -$21000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn -
5 Akari Therapeutics 605.66 Bn 605.66 Bn -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn
8 Evaxion A 65.12 Bn 65.10 Bn -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn
10 Lyra Therapeutics - - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 238,000.00
Sep 30, 2025 -21,000.00
Jun 30, 2025 398,000.00
Mar 31, 2025 900,000.00
Dec 31, 2024 1.65 Mn
Sep 30, 2024 2.80 Mn
Jun 30, 2024 6.45 Mn